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Abstract
The formation of reactive oxygen species (ROS) within cells causes damage to biomolecules, including membrane lipids,
DNA, proteins and sugars. An important type of oxidative damage is DNA base hydroxylation which leads to the formation
of 8-oxo-7,8-dihydro-29-deoxyguanosine (8-oxodG) and 5-hydroxymethyluracil (5-HMUra). Measurement of these bio-
markers in urine is challenging, due to the low levels of the analytes and the matrix complexity. In order to simultaneously
quantify 8-oxodG and 5-HMUra in human urine, a new, reliable and powerful strategy was optimised and validated. It is
based on a semi-automatic microextraction by packed sorbent (MEPS) technique, using a new digitally controlled syringe
(eVolH), to enhance the extraction efficiency of the target metabolites, followed by a fast and sensitive ultrahigh pressure
liquid chromatography (UHPLC). The optimal methodological conditions involve loading of 250 mL urine sample (1:10
dilution) through a C8 sorbent in a MEPS syringe placed in the semi-automatic eVolH syringe followed by elution using
90 mL of 20% methanol in 0.01% formic acid solution. The obtained extract is directly analysed in the UHPLC system using
a binary mobile phase composed of aqueous 0.1% formic acid and methanol in the isocratic elution mode (3.5 min total
analysis time). The method was validated in terms of selectivity, linearity, limit of detection (LOD), limit of quantification
(LOQ), extraction yield, accuracy, precision and matrix effect. Satisfactory results were obtained in terms of linearity (r2 .
0.991) within the established concentration range. The LOD varied from 0.00005 to 0.04 mg mL21 and the LOQ from 0.00023
to 0.13 mg mL21. The extraction yields were between 80.1 and 82.2 %, while inter-day precision (n= 3 days) varied between
4.9 and 7.7 % and intra-day precision between 1.0 and 8.3 %. This approach presents as main advantages the ability to easily
collect and store urine samples for further processing and the high sensitivity, reproducibility, and robustness of eVolHMEPS
combined with UHPLC analysis, thus retrieving a fast and reliable assessment of oxidatively damaged DNA.
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Introduction
Oxidative stress results from an imbalance between the
generation of reactive oxygen species (ROS) and antioxidant
defences. It occurs when excessive production of ROS overwhelms
the antioxidant defence system, when there is any condition
affecting the antioxidant defences or a combination of both factors
[1,2]. Oxidative stress is known to cause damage to biomolecules,
namely membrane lipids, DNA, proteins and sugars, a condition
known as oxidative damage. This damage is particularly harmful
to DNA when there are mutations in tumour suppressor genes that
are not corrected, triggering critical initial events in carcinogenesis
[3]. This attack to DNA generates a wide range of base and sugar
modification products that include single- or double-stranded
DNA breaks, purine, pyrimidine, or deoxyribose modifications,
and DNA cross-links (reviewed in [4]). Over one hundred of such
oxidatively modified DNA forms have been characterised in vitro
[5], but only about 20 identified in vivo [4] and found to be
involved in the induction of signal transduction pathways,
replication errors and genomic instability and transcription
induction or arrest [6]. These results are strongly supported by,
for example, the high levels of oxidative lesions in cancer tissues,
and reduced cancer incidence in populations with high dietary
antioxidant intake [7]. Breast and lung cancers are two
particularly prevalent forms of cancer worldwide, being breast
cancers, more intimately related to DNA damage repair defects or
defects in cell-cycle checkpoints which allow damaged DNA to go
unrepaired [8], while in lung cancer, unrepaired DNA damage
and genomic instability predominate [9]. Therefore, assessment of
DNA damage is very important and this can be performed by
quantifying oxidatively modified DNA adducts such as 8-oxodG
(reviewed in [10]). 8-oxodG results from the oxidation of guanine
at the C8 position, leading to site-specific mutagenesis in bacterial
and mammalian cells through G-T transversions that are widely
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found in mutated oncogenes and tumour suppressor genes [6].
Moreover, elevated levels of oxidative DNA lesions, namely 8-
oxodG, have been noted in various tumours, strongly implicating
such damage in the etiology of cancer, most probably in the
initiation process [11]. Although less studied, 5-HMUra is another
important and frequent oxidative DNA lesion and can result from
the hydroxylation of thymine, forming the HmU:A mismatched
base pair, or hydroxylation followed by deamination of 5-
methylcytosine, resulting in HmU:G base pair formation
[12,13]. Therefore, 5-HMUra is also used to assess oxidative
damage to DNA [14]. In Figure 1 are represented the structures of
both biomarkers.
The extraction methods developed for the analysis of bio-
markers of oxidatively modified DNA, generally, includes extrac-
tions with solvents, clean-up and further fractionation by liquid–
liquid extraction (LLE) [15], or solid phase extraction (SPE)
[16,17]. However, these procedures are quite time-consuming and
need a relatively high volume of solvent/sample, which is
impractical for the routine analyses. In clinical laboratories the
main requirements for sample preparation are celerity, simplicity
and miniaturisation of the experimental procedures, especially
when using small sample volumes and organic solvents, while
maintaining sufficient selectivity, precision and accuracy [18].
Microextraction by packed sorbent (MEPS), as a miniaturised
SPE, was a logical extension of that technique for the sample
preparation of biological fluids, presenting several advantages. It
can handle both small sample and large volumes (from 10 mL up
to 1000 mL) and is suitable for normal phases, reversed phases,
mixed mode and ion exchangers. Therefore, MEPS can substitute
most existing methods using SPE just by scaling down the solvents
and sample volumes. This approach is much less expensive
because the MEPS syringe can be used several times, up to 100
times or more, while conventional SPE columns and cartridges are
used only once. Moreover, its utilisation prior to liquid chroma-
tography is an excellent tool for screening the presence of drugs
and metabolites in blood, plasma and urine samples. It was already
used to extract a wide range of analytes of interest in biological
matrices, namely antiepileptic [19] and psychotropic drugs, local
anaesthetics and their metabolites, anticancer drugs and the
neurotransmitters dopamine and serotonin (reviewed in [20]).
Current quantification methods for 8-oxodG analysis are
mainly immunological (enzyme-linked immune sorbent (ELISA)
assays [21,22]) or chromatographic (HPLC with electrochemical
detection (HPLC-ECD) [23], capillary electrophoresis with
electrochemical detection (CE-ECD) [24], HPLC coupled to mass
spectrometry detection with electrospray ionisation (HPLC-ESI-
MS/MS) [25], or gas chromatography coupled with mass
spectrometry detection (GC-MS) [24]). In turn, 5-HMUra
quantification has been reported only a few times and using
a GC-MS approach [13,26,27]. The improvement of HPLC
technology leads to UHPLC development that very rapidly
became a new standard in separation sciences. Very recently,
Lam et al. (2012) presented a methodology to quantify 8-oxodG in
several human fluids using UPLC-MS/MS [28].
The present research study reports, for the first time, to the best
of our knowledge, the development and validation of an ultrafast,
efficient, sensitive, reliable and high throughput MEPS eVolH-
based methodology in combination with UHPLC–PDA for the
simultaneous determination of two urinary biomarkers of oxida-
tively damaged DNA, 5-HMUra and 8-oxodG, in cancer (lung
and breast) patients and healthy subjects (control). Chromato-
graphic conditions were optimised in order to achieve increased
sensitivity and high resolution on the target metabolites while
maintaining reduced analysis time (less than 3.50 min). The levels
Figure 1. Chemical structures of 8-hydroxy-29-deoxyguanosine (8-oxodG), 5-hydroxymethyluracil (5-HMUra) and cimetidine (used
as internal standard - IS).
doi:10.1371/journal.pone.0058366.g001
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of the metabolites are evaluated and compared in order to
determine their potential for cancer diagnosis as a first approach.
We then compared the alterations in the oxidatively damaged
DNA profiles between the cancer patients and the controls using
univariate and multivariate analyses.
Materials and Methods
Ethics Statement
All cancer patients and healthy subjects gave their written
informed consent for inclusion in the study and the research was
approved by the Ethics Committee of the Dr. Ne´lio Mendonc¸a
Hospital (Funchal, Portugal), being done in accordance with the
Good Clinical Practice guidelines and with the ethical guidelines
of the 1975 Declaration of Helsinki. All data were analysed
anonymously throughout the study.
Subjects and Sample Collection
The subjects were divided into healthy subjects (control group)
and cancer (breast and lung) patients. The characterisation of the
groups is shown in Table 1.
The normal controls (n = 20, age = 48.7 6 17.6 y) were selected
among the blood donors at the Dr. Ne´lio Mendonc¸a Hospital and
had no clinical history of cancer. The patients (breast cancer
n = 10, age = 57.1 6 11.7 y; lung cancer, n= 10, age = 54.8 6
10.8 y) underwent different diagnostic procedures, such as breast
physical examination, mammography and ultrasonography, mag-
netic resonance imaging and chest X-ray and finally histologically
diagnosed with primary cancer by the Haematology–Oncology
Unit of the Dr. Ne´lio Mendonc¸a Hospital.
Each individual (either patient or healthy volunteer) provided
a sample of morning urine (after overnight fasting) in a 20 mL
sterile PVC container. The samples were immediately frozen at
280uC and kept until being processed.
Standard Preparation and Urine Samples
Individual standard solutions of oxidatively damaged DNA
biomarkers (1000 mg mL21) were prepared in pure water, aliquot
in 4 mL vials, and stored at 220uC. Under these conditions they
were stable for at least 4 months (as assessed by UHPLC). Working
standard solutions containing the oxidative stress biomarkers were
prepared daily from the individual stock solutions by diluting them
in the synthetic urine (SU, prepared as described by Uppuluri et al.
[29]).
The ranges of concentrations (see Table 2) were selected
according to the sensitivity of the UHPLC–PDA towards each
biomarker (as the physical-chemical characteristics of each
compound affect its analytical signal, higher concentrations had
to be used for some compounds in order to be possible their
detection). In all measurements (standards and samples) cimetidine
was used as internal standard (IS). All samples were analysed in
triplicate and their pH previously adjusted to 6 with 0.1 M sodium
hydroxide or 0.01 % formic acid and filtered through 0.22 mm
membrane PTFE filters.
MEPS Extraction using eVolH
The MEPS procedure was carried out with an eVolH semi-
automatic syringe (SGE Analytical Science, Melbourne, Australia),
consisting of a 500 mL gas-tight syringe with a removable needle.
The syringe was fitted with a BIN containing 4 mg of the
sorbent material through which samples and solutions were
Table 1. The characteristics of subjects (Age, Gender,
Smoking habits, Medication).
Cancer Patients
Control Breast Lung
Age 21–40 7 1 1
41–60 7 5 6
61–80 6 4 3
Gender Male 9 – 7
Female 11 10 3
Smoking Habits Yes 1 2 3
No 19 8 5
Ex – – 2
Medication Yes 9 8 9
No 11 2 1
doi:10.1371/journal.pone.0058366.t001
Table 2. Figures of merit of the newly developed eVolH-
MEPS/UPLC-PDA methodology.
Biomarkers 5-HMUra 8-oxodG
Peak number 1 3
RT (min) 1.05 1.80
lmax
a (nm) 215 295
Analytical performance
Conc. range (mg mL21) 0.0005 – 0.01 0.1–5
Regression equation y= 1277.5x + 0.8318 y=0.0724x + 0.0052
b r2 0.9906 0.9946
LODc (mg mL21) 0.00005 0.04
LOQd (mg mL21) 0.00023 0.13
% Matrix effect 80.1 82.2
Fortification level (mg mL21)e LL 0.0005 0.1
ML 0.0025 1.5
HL 0.01 5.0
Accuracy (%)e LL 91.0 94.7
ML 95.5 96.8
HL 104.7 103.5
Extraction yield (%)e LL 89.4 63.5
ML 98.5 73.7
HL 99.9 101.8
Intra-day (n = 7) RSD(%)e LL 5.7 8.3
ML 4.2 4.8
HL 0.9 2.0
Inter-day (n= 25) RSD(%)e LL 7.7 6.1
ML 7.7 5.8
HL 6.1 4.9
aMaximum absorbance values obtained in the PDA system detection;
bCorrelation coefficient, give an estimating how well the experimental points fit
a straight line;
cLimit of detection;
dLimit of quantification. Values obtained from ordinary least-squares regression
data.
eConcentration levels used in eVolHMEPS/UPLC-PDA validation studies: LL-low
level; ML- medium level; HL- high level.
doi:10.1371/journal.pone.0058366.t002
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discharged. A SU sample spiked with known amounts of oxidative
stress biomarkers was used to optimize the MEPS procedure. The
flow rate during aspiration was limited to 20 mL s21 to prevent
cavitation. This also increases analyte/sorbent contact time and
extraction efficiency. All optimization procedures were carried out
in triplicate. Before each use, the sorbent was conditioned with
100 mL of methanol followed by 0.01 % formic acid. This step
activates the sorbent and ensures reproducible retention of the
analytes between extractions, decreasing memory effects (carry-
over) [20].
UHPLC-PDA Analysis and Operating Conditions
The analysis of oxidative stress biomarkers were carried out on
a Waters Ultra Performance Liquid Chromatographic Acquity
system (UPLC, Acquity H-Class) (Milford, MA, USA) combined
with a Waters Acquity quaternary solvent manager (QSM), an
Acquity sample manager (SM), a column heater, a PDA detector,
and a degassing system. The whole configuration was driven by
Empower software v2.0 (Waters Corporation). Optimum separa-
tion was achieved with a binary mobile phase which consisted of
(A) water at 0.01% formic acid, and (B) methanol, with a constant
flow rate of 250 mL min21, giving a maximum back pressure of
6.000 psi, which is within the capabilities of the UHPLC. The
extracts (2 mL) were injected into the UPLC system, equipped with
an Acquity UPLCTM strength silica HSS T3 analytical column
(1.8 mm particle size, 2.16100 mm) protected with an Acquity
UPLCTM HSS T3 Van GuardTM Pre-column (Waters, Milford,
USA). The column temperature was thermostated at 30uC and the
samples were kept at 15uC in the sample manager. The sample
analysis was performed with an isocratic flow of 80 % A at 250 mL
min21 during 3.50 min followed by a re-equilibration time of
3 min. All solvents and samples were filtered through 0.22 mm
PTFE filters (Millipore, Milford, USA), before use. For quantifi-
cation purposes the PDA detection was conducted by using four
distinct channels that were set to the maximum absorbance
wavelength of each biomarker, as indicated in Table 2. They were
identified by comparing the retention time and spectral char-
acteristics of their peaks.
Method Validation Design
The eVolHMEPS/UHPLC-PDA newly developed method for
determination of urinary biomarkers of oxidatively damaged DNA
was fully validated in terms of selectivity, linearity, limits of
detection (LOD) and quantification (LOQ), inter- and intra-day
precision, accuracy, extraction efficiency and matrix effect
(Table 2). The selectivity of the method was assessed by the
absence of interfering peaks at the elution times of 5-HMUra and
8-oxodG. Method linearity was evaluated by constructing three
calibration curves (the peak areaanalyte/peak areaIS ratios obtained
were plotted against the corresponding standard concentration) for
each biomarker using standard solutions prepared in SU from
individual stock solutions. It were prepared eight different
concentration levels in triplicate for each point (n= 9), including
zero point, in order to cover the whole working range (Table 2).
The zero point (unspiked SU) enables the verification that none of
the compounds showed residual level or background signal. The
sensitivity of the method was assessed by determining the LOD
(the lowest analyte concentration that produces a response detect-
able above the noise level of the system) and LOQ (the lowest level
of analyte that can be accurately and precisely measured) for each
compound. LOD and LOQ were calculated with the data
generated in the linearity studies, being LOD defined as (a+3Sa/
b) and LOQ as (a+10Sa/b), where ‘‘a’’ represents origin ordinate,
‘‘Sa’’ the origin ordinate variance and ‘‘b’’ the slope [30]. These
parameters were calculated for each analyte from the standard
solutions used to obtain the corresponding calibration curves,
using the developed UHPLC method.
Precision is a function of the concentration and describes the
closeness of agreement between series of measurements, facilitat-
ing comparisons of variability at different concentrations. Method
precision was evaluated by spiking a SU at three different
concentration levels, corresponding to the low level (LL), medium
level (ML) and highest point (HL) of the calibration curve of each
biomarker (Table 2). Six replicates (n= 6) were performed in the
same day to obtain repeatability (intra-day precision). For inter-
day precision (intermediate precision) evaluation, the same
protocol was followed but six replicates of each level were
analysed daily through three different days (n = 24).
In order to check the accuracy of the proposed method
a recovery study was carried out by spiking SU, in triplicate at
three concentration levels corresponding to the LL, ML and HL
(Table 2), and subjected to the eVolHMEPS procedure above
(section 2.4.1). The recovery values were calculated according to the
following formula: Accuracy = 1006([analyte]after spiking – [analyte]-
before spiking)/[analyte]added; where [analyte]after spiking is the analyte
concentration measured in spiked urine; [analyte]before spiking is the
analyte concentration measured in unspiked urine, and [analy-
te]added is the nominal concentration of the analyte added to urine.
Extraction efficiency (EE) was determined by replicate analysis
(n = 3) of SU spiked with oxidative stress biomarkers at three
concentration levels (LL, ML, and HL; see Table 2) and submitted
to eVolHMEPS procedure (CSU_MEPS); a second set of different
aliquots of SU was submitted to eVolHMEPS and the extracts
spiked with the 5-HMUra and 8-oxodG biomarkers at LL, ML,
and HL concentration levels (CSU). The peak area ratio obtained
for spiked SU matrix before and after eVolHMEPS was used to
calculate the corresponding concentration through regression
analysis (interpolation of signals in calibration graphs). The matrix
effect was evaluated by the percentage of the quotient between the
slopes of the standards in blank matrix (SU) and those obtained by
spiking urine (standard addition method).
Statistical Analysis
Significant differences among the three extraction techniques
were assessed with a one-way analysis of variance (ANOVA) using
a SPSS Program, version 19.0 (SPSS Inc. Headquarters, Chicago
IL, USA). Figures and tables were generated using Microsoft
Office Excel 2007 (Microsoft Corporation, Redmond, WA, USA).
Results
Optimisation of the MEPS Procedure
To optimise the MEPS procedure, important experimental
parameters with influence on the extraction performance, namely
sorbent type, sample pH, sample volume, and elution conditions,
were carefully investigated. Each one of the commercially
eVolHMEPS sorbents (the silica-based C2, C8, C18, SIL and the
mixed-mode M1 (C8/strong cation exchanger (SCX)), was
evaluated. The selection of the best sorbent was based on
extraction efficiency, determined by the relative peak area, and
reproducibility. As shown in Figure 2A, the highest relative peak
areas for both biomarkers (5-HMUra and 8-oxodG) were obtained
with C8 sorbent. In contrast, the lowest extraction efficiency was
obtained by using M1 and SIL sorbents, respectively. C8 sorbent
was, therefore, chosen as the best stationary phase and was used
for more than 100 extractions without loss of efficiency, as assessed
by the UHPLC-PDA data generated.
Urinary Biomarkers of DNA Damage by UHPLC
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The influence of pH on the extraction efficiency was evaluated
by assaying samples with pH adjusted to 2, 6 and 8 (using 0.1M
sodium hydroxide solution or 0.01% formic acid). The results
(Figure 2B) showed that pH 2 enables the best results for 5-
HMUra, while pH 6 is slightly better for 8-oxodG. However, the
peak resolution for both biomarkers is much better at pH 6 (data
not shown) and urine pH usually range between 6 and 7 [31].
Therefore, pH 6 was chosen to perform the analytical extraction
of the target biomarkers. The effect of the number of extraction
cycles (extract–discard) and sample volume on extraction efficien-
cy of the biomarkers was shown in Figure 2C. The best result for
5-HMUra was obtained with five extraction cycles for 50 mL or
250 mL of sample volume, while for 8-oxodG were five extraction
cycles for 50 mL and ten extraction cycles for 100 or 250 mL of
sample volume. As there was no significant improvement in the
two biomarkers extraction efficiency by using higher sample
volumes, five extraction cycles of 50 mL sample volume loading
were used. This choice of using low sample volume loads several
times (5) has additional advantages of extending the lifetime of the
MEPS cartridge and minimisation of possible interferences of
other urine compounds in the target biomarkers quantification.
The elution conditions were also assayed and, as shown in
Figure 2D, the extraction efficiency was not significantly affected
by the increase in the number or volume of elutions. Therefore, it
was chosen to elute the target analytes with three times 30 mL of
methanol / 0.01 % formic acid (elution solution).
Method Validation
The method performance parameters were calculated for each
biomarker using concentrations usually found in human urine.
The validation parameters are shown in Table 2.
The selectivity of the new approach was assessed by the absence
of interference in the same chromatographic windows as examined
in a solution of standards of both biomarkers and analysis of
‘‘blank matrices’’ (SU). No interfering peaks were observed in the
blank chromatograms at the quantification wavelengths (215 and
295 nm for 5-HMUra and 8-oxodG, respectively, see Figure 3).
Linearity of the method was established on spiked urine samples
prepared and analysed using the described extraction procedure in
the range of 0.005–0.01 mg mL21 for 5-HMUra and 0.1–5 mg
mL21 for 8-oxodG (six calibrators evenly distributed, three
replicates). The UHPLC–PDA system gave linear response over
the studied range of concentrations and the least-squares linear
regression analysis of the data provided excellent correlation
coefficient values for 5-HMUra (r2 . 0.9906) and 8-oxodG (r2 .
0.9946). The calibration was performed by using SU spiked with
the calibration standards prepared as previously described
(Material and Methods). The eVolHMEPS/UHPLC–PDA meth-
odology allows very low detection (0.00005 mg mL21 and 0.04 mg
mL21) and quantification limits (0.00023 and 0.13 mg mL21) for
5-HMUra and 8-oxodG, respectively. This sensitivity is sufficient
to quantify the target biomarkers in biological fluids.
The precision values are satisfactory, with relative standard
deviation (RSD) values lower than 8.5 % for each measured
analyte at all spiking levels (Table 2). The intra-day precision at
the three different levels ranged from 1.0 % (5-HMUra at HL
concentration) to 8.3 % (8-oxodG at LL concentration), while the
inter-day precision varied from 5.0 % (8-oxodG at HL concen-
tration) to 7.7 % (5-HMUra at ML concentration).
The accuracy of the method was determined according to the
equation presented in method validation design section. The mean
accuracies obtained for the target biomarkers (n = 6) at each
fortification level are listed in Table 2. At high concentrations, the
results were satisfactory and ranged between 95.5 % and 104.7 %,
and at low concentrations the recovery was slightly lower (91.0 %).
The results showed that the absolute extraction yield increased
Figure 2. Optimisation results of the eVolHMEPS extraction methodology for quantification of oxidatively damaged DNA
biomarkers in urine. (A) Comparison the performance characteristics (relative peak areas - AC/AIS, obtained for each adsorbent) of different MEPS
adsorbents for isolation of target DNA damage biomarkers from urine; (B) effect of pH value on the extraction efficiency; (C) influence of number of
extraction cycles (extraction-discard) as a function of applied sample volume; (D) effect of elution volume on UHPLC-PDA response. Errors bars show
the standard deviation of the mean (n=3).
doi:10.1371/journal.pone.0058366.g002
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slightly from low concentration levels (89.4 % for 5-HMUra, and
63.5 % for 8-oxodG) to medium (98.5 % 5-HMUra, and 73.7 %
for 8-oxodG) and high concentration levels (99.9 % for 5-HMUra,
and 91.0 % for 8-oxodG). To evaluate the impact of the matrix on
the target analytes, the slopes obtained in the calibration with
matrix-matched standards were compared with those obtained
with solvent-based standards, calculating matrix/solvent slope
ratios for each of both metabolites (Table 2). We consider that the
matrix effect could be ignored if the matrix/solvent slope ratio
values were in the range of 85 % – 110 %, below that limit,
a matrix suppression effect is observed and above 110% there is
matrix enhancement [32]. Based on the results obtained (80 %
and 82 % for 5-HMUra and 8-oxodG, respectively) a moderate
matrix effect was observed and, therefore, matrix-matched
calibration solutions were used for quantification purposes, in
order to compensate the referred errors.
Quantification of 8-oxodG and 5-HMUra by eVolHMEPS /
UHPLC-PDA
The assays were carried out using SU as the development
method matrix. After method validation, and in order to
demonstrate its applicability, a total of forty urine samples (lung
and breast cancer patients and healthy subjects) were analysed in
triplicate. Both biomarkers were identified by the retention time
and UV spectra obtained at the maximum absorbance wavelength
(lmax = 215 nm and 295 nm for 5-HMUra and 8-oxodG, re-
spectively). A typical chromatogram of control, lung and breast
cancer patients urine obtained through eVolHMEPS / UHPLC-
PDA developed methodology, is shown in Figure 3.
As can be observed, excellent peak shape and resolution were
achieved with minimal interference from other components of the
urine matrix. Moreover, all urine profiles are quite similar, despite
the clinical condition of the donor, except for the concentrations of
each biomarker analysed.
With respect to the controls, twenty urine samples (n = 20), were
analysed, and the mean values obtained of 2.961024 6 3.0 (RSD
(%)) mg mL21 and 1.961021 6 4.4 (RSD (%)) mg mL21 for 5-
HMUra and 8-oxodG, respectively. Regarding cancer patients,
ten lung cancer patients (n = 10) and ten breast cancer patients
(n = 10) were analysed. For lung cancer patients, the mean values
obtained were 2.361024 6 3.2 (RSD (%)) mg mL21 and
2.661021 6 3.9 (RSD (%)) mg mL21 for 5-HMUra and 8-
oxodG, respectively. With respect to the breast cancer patients, the
mean concentrations were 3.161024 6 2.6 (RSD (%)) mg mL21
and 4.461021 6 5.2 (RSD (%)) mg mL21 for 5-HMUra and 8-
oxodG, respectively. These results can be more easily compared
by viewing Figure 4.
Figure 3. Representative UHPLC-PDA chromatograms of a biomarker standard solution (5-HMUra at 0.0025 mg mL21; 8-oxodG at
4 mg mL21) (A), and from urine of control subjects and cancer (lung and breast) patients (B).
doi:10.1371/journal.pone.0058366.g003
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Discussion
The optimization of MEPS procedure involved several factors
and conditions described in the previous section. The best
cumulative sorbent for both biomarkers, C8, is in agreement with
the fact that C2–C8 phases are more suitable for lipophilic
analytes (non-polar) and polymeric phases such as polystyrene–
divinylbenzene, while mixed mode phases (anion–cation exchange
mode) are more suitable for polar analytes such as acidic and basic
compounds [33]. Moreover, C8 sorbents present extra properties,
allowing secondary interactions with polar groups from the
analyte. However it should be noted that 8-oxodG is much more
selective in the interaction with the stationary phases, with C2 and
SIL retrieving very low responses when compared with remain
sorbents. In turn 5-HMUra interacts more favourably with all
sorbents (Figure 2). In MEPS, the retention of the analytes in the
sorbent phase is affected by the number of extraction cycles
performed and the speed applied. Experimentally, the multiple
extraction cycles can be performed using the same aliquot (draw–
eject in the same vial) or by drawing up from the aliquot and
discarding in waste (extract–discard). This last option was selected
in this study. Figure 2C shows that the competition for active
adsorption sites of the C8 sorbent increased slightly until five
extraction cycles. However, the volume of sample loading is not
directly proportional to the increase of relative area.
Regarding the method performance, the results obtained
demonstrated a good linearity for both biomarkers investigated,
within the tested concentration range for the whole extraction and
determination method. In general, acceptable recoveries and
precision were obtained for 5-HMUra and 8-oxodG at three
different spiked levels. Furthermore, optimised UHPLC-PDA
offers good sensibility and selectivity for the target analytes.
The obtained results for the extraction yields showed low
extraction efficiency at low concentration level (LL) for 5-HMUra
and 8-oxodG, than those obtained with the middle (ML) and high
(HL) fortification levels. The reason for this may be due to the fact
that the surface chemistry of the sorbent can be altered by
interfering compounds from urine and, therefore, sorption
properties can change [34]. This effect is more pronounced at
low concentrations of the analyte when the analyte/matrix ratio is
very low. The same behaviour was observed for the accuracy
measurements. Despite this, the results show that eVolHMEPS/
UHPLC-PDA is a good methodology to quantify 5-HMUra and
8-oxodG in human urine. Unfortunately, there are no reference
ranges for 8-oxodG and 5-HMUra in healthy or diseased
individuals [35] and we can only compare our results with the
ones reported by others using similar methodologies. In this
respect, Harri et al. (2007) [15], using HPLC-MS/MS, reported
lower values than ours for 8-oxodG (8-oxodG concentrations
ranging from 0.16 to 16.48 mg L-1, LOD = 0.005 mg L21 and
LOQ = 0.16 mg L21). Regarding 5-HMUra, we only find one
study [26] referring to the concentration of 121 pmol mL21 for
this biomarker, but using HPLC-GC-MS, which makes it very
difficult to compare methodologies.
Forty human urine samples (20 normal controls; 10 lung cancer
patients and 10 breast cancer patients) were used in the study. As
shown in Figure 3, the separation of the standard mixture of the
biomarkers of DNA oxidation is very fast, being achieved in less
than 3.50 min. The chromatograms present a good peak shape
and resolution was achieved for both compounds with no
interference from urine matrix (Figure 3). The chromatograms
obtained for control individuals and for breast and lung cancer
patients showed quite similar profiles (Figure 3), since the
concentrations of both biomarkers in the samples are very low
to present any significant difference in the overall chromatogram.
Accordingly, with these results, the concentration of 5-HMUra
does not present significant differences between controls subjects
and breast patients showing a slight decrease in lung cancer
patients. In turn, 8-oxodG presents more pronounced differences
between control, the lowest levels, lung cancer patients, in-
termediate levels which are almost twice the control levels, and
breast cancer patients, that present values that are three times
higher than controls.
There are few studies showing that the levels of urinary 8-
oxodG increases in breast and lung cancer patients [36,37,38], but
to our knowledge, our study is the first one reporting the
simultaneous quantification of 8-oxodG and 5-HMUra, using
a MEPS-UHPLC-PDA approach, which is much more reliable
than the referred studies using ELISA assays. Overall, the
combination of eVolHMEPS together with quick UHPLC-PDA
Figure 4. Total concentration of oxidatively damaged DNA investigated biomarkers in normal controls, and in breast and lung
cancer patients.
doi:10.1371/journal.pone.0058366.g004
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system, proved to be an improved strategy, with excellent
recoveries, sensitivity, and repeatability, making it possible to
use, as a rapid approach, to analyse the biomarkers present in
human urine. Moreover, the combination of eVolH and MEPS
offers improvements in workflow and accuracy of the extraction
process, because, unlike conventional SPE columns, the MEPS
sorbent bed can be easily integrated into a liquid-handling syringe,
as the semiautomatic syringe eVolH, allowing for low void volume
sample manipulations and the full automation of the sample
processing, extraction and injection steps. Recently, Lam et al.
[28] quantified 8-oxodG in several human matrices using a SPE-
LC-MS approach. The methodology we are now proposing can be
considered an improvement to Lam’s report because the use of
MEPS instead of SPE certain would benefit their work.
Furthermore, the methodology would be an alternative to
assessing oxidative damage to DNA when MS detection is not
available, as the MEPS-UHPLC approach presents enough
sensitivity and is much less expensive, and is more environment-
friendly than the previous one.
In summary, a robust, rapid and fully validated procedure is
described for the detection and high-throughput quantification of
oxidatively-damaged DNA biomarkers in human (healthy subjects
and cancer patients) urine samples, using MEPS/UHPLC-PDA.
This method has shown to be linear within the adopted ranges for
both biomarkers, and presented adequate accuracy and precision.
Furthermore, the procedure can be useful for those laboratories
performing routine urine analysis in the field of both clinical and
medicinal chemistry.
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